MLTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ML

Mkt Cap

$811.5M

Volume

969.31K

Next Earnings

November 4th

Loading chart

ML

MLTXMoonLake Immunotherapeutics Class A Ordinary Shares

MLTX

Pay with—

Available Balance0.00

ML

Mkt Cap

$812.8M

Volume

969.31K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsightThe psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.GlobeNewswire Inc. · Sep 21, 2026

MoonLake Immunotherapeutics' CFO Sells 39K SharesMoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 39,120 shares worth approximately $862,000 on June 22 through a pre-planned 10b5-1 trading plan. The sale represented 3.4% of his direct holdings, leaving him with over 1.1 million shares. While the transaction shouldn't concern investors due to its pre-planned nature, the clinical-stage biotech company remains highly volatile with no approved products or revenue.The Motley Fool · Jul 3, 2026

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public OfferingMoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotech company, announced the pricing of an underwritten public offering of 9 million Class A ordinary shares at $20.00 per share and 1 million pre-funded warrants, expected to raise approximately $200 million in gross proceeds. The company plans to use the net proceeds to fund research, development, and commercialization activities for sonelokimab, its investigational treatment for inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis. The offering is expected to close on or about June 25, 2026.GlobeNewswire Inc. · Jun 24, 2026

The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold 150,000 shares worth approximately $2.8 million on April 10-13, 2026, reducing his direct holdings by 4.9%. While the sale is not necessarily alarming given his substantial remaining stake of nearly 3 million shares, the company remains a high-risk investment. MoonLake's stock has fallen 47.47% over the past year following disappointing clinical trial results for its lead therapy Sonelokimab, though the FDA granted it fast-track designation. The pre-revenue biotech company burns approximately $65 million quarterly but has $394 million in cash reserves.The Motley Fool · Apr 18, 2026

Biotech Fund BVF Trims MoonLake Stake, Sells $63M in SharesBVF Partners L.P., a biotech-focused hedge fund, sold 3.75 million shares of MoonLake Immunotherapeutics for approximately $63 million on April 2, 2026, reducing its direct stake by 78.3%. The sale appears to be portfolio rebalancing rather than a full exit, as BVF retains 15.9 million shares. MoonLake, a clinical-stage immunotherapy company developing sonelokimab for inflammatory diseases, has experienced a 53.35% stock decline over the past year despite recent positive clinical trial results.The Motley Fool · Apr 7, 2026

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual MeetingMoonLake Immunotherapeutics announced Week 40 results from its Phase 3 VELA clinical trials of sonelokimab (SLK) for moderate-to-severe hidradenitis suppurativa (HS). The drug demonstrated continued clinical improvement with 62% of patients achieving HiSCR75 response and up to 32% achieving HiSCR100. Patients also showed substantial improvements in quality of life measures, with up to 25% achieving inflammatory remission. No new safety signals were detected. The company expects to present detailed results at the 2026 AAD Annual Meeting and has upcoming milestones including 52-week data readout and BLA submission in H2 2026.GlobeNewswire Inc. · Mar 28, 2026

MoonLake Finds Its Footing as FDA Wins Reset the Risk-Reward ProfileMoonLake Immunotherapeutics has rallied over 30% in the past month following FDA regulatory victories. The company received Fast Track designation for Sonelokimab in treating Palmoplantar Pustulosis and FDA confirmation that existing data is sufficient for approval in Hidradenitis Suppurativa. With $380.5 million in cash runway extending into late 2027, the company has de-risked its investment profile. An upcoming Investor Day on February 23, 2026 will showcase Phase 2 trial data, with potential short squeeze dynamics given 12.7% short interest.Investing.com · Feb 4, 2026

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor DayMoonLake Immunotherapeutics announced that the FDA has granted Fast Track designation for sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP), based on positive Phase 2 LEDA trial results. The designation enables more frequent FDA interactions and potential expedited review pathways. The company will discuss this milestone and provide updates on multiple clinical programs at an Investor Day on February 23, 2026, including Phase 2 S-OLARIS data in axial spondyloarthritis and progress toward a BLA submission for hidradenitis suppurativa in H2 2026.GlobeNewswire Inc. · Feb 2, 2026

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm is pursuing a class action lawsuit against MoonLake Immunotherapeutics for allegedly making false and misleading statements about its drug candidate sonelokimab, which led to a significant stock price drop after disappointing Phase 3 trial results.Benzinga · Dec 15, 2025

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm is pursuing a securities fraud lawsuit against MoonLake Immunotherapeutics, alleging the company made false claims about its drug candidate sonelokimab and misled investors about its treatment superiority, resulting in a 90% stock value loss.Benzinga · Dec 15, 2025

to start trading

ML

MLTXMoonLake Immunotherapeutics Class A Ordinary Shares

MLTX

Pay with—

Available Balance0.00

Your PositionYou don't own any MLTX yet.

Related Tickers

Earnings